DHI vs SPRY · P/E 9.6, rev $34.25B vs rev $56.3M
DR Horton Inc (DHI) versus ARS Pharmaceuticals, Inc (SPRY) — a side-by-side from cached financials, not a winner call.
DR Horton Inc (DHI) is a residential construction company listed on US.
ARS Pharmaceuticals, Inc (SPRY) is a biotechnology company listed on NASDAQ.
Latest reported DHI revenue for 2025-09-30 was $34.25B. Net income was $3.62B. DHI currently screens at market cap $39.10B and trailing P/E 9.6.
Latest reported SPRY revenue for 2026-06-30 was $56.3M. Net income was -$123.0M. SPRY currently screens at market cap $983.1M.
DHI currently screens at market cap $39.10B and trailing P/E 9.6. SPRY currently screens at market cap $983.1M.
Not investment advice. Open the DHI and SPRY stock pages for the full models.
Not investment advice.